SG11202002826VA - Immunomodulatory fusion proteins - Google Patents
Immunomodulatory fusion proteinsInfo
- Publication number
- SG11202002826VA SG11202002826VA SG11202002826VA SG11202002826VA SG11202002826VA SG 11202002826V A SG11202002826V A SG 11202002826VA SG 11202002826V A SG11202002826V A SG 11202002826VA SG 11202002826V A SG11202002826V A SG 11202002826VA SG 11202002826V A SG11202002826V A SG 11202002826VA
- Authority
- SG
- Singapore
- Prior art keywords
- fusion proteins
- immunomodulatory fusion
- immunomodulatory
- proteins
- fusion
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 230000002519 immonomodulatory effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5428—IL-10
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762564145P | 2017-09-27 | 2017-09-27 | |
PCT/US2018/053197 WO2019067770A1 (en) | 2017-09-27 | 2018-09-27 | IMMUNOMODULATORY FUSION PROTEINS |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202002826VA true SG11202002826VA (en) | 2020-04-29 |
Family
ID=65902489
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202002826VA SG11202002826VA (en) | 2017-09-27 | 2018-09-27 | Immunomodulatory fusion proteins |
Country Status (13)
Country | Link |
---|---|
US (2) | US11834492B2 (ja) |
EP (1) | EP3688037A4 (ja) |
JP (2) | JP2020536518A (ja) |
KR (1) | KR20200057070A (ja) |
CN (1) | CN111511769B (ja) |
AU (1) | AU2018338612A1 (ja) |
BR (1) | BR112020006115A2 (ja) |
CA (1) | CA3077223A1 (ja) |
EA (1) | EA202090838A1 (ja) |
IL (1) | IL273626A (ja) |
MX (1) | MX2020003672A (ja) |
SG (1) | SG11202002826VA (ja) |
WO (1) | WO2019067770A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7421338B2 (ja) | 2016-09-27 | 2024-01-24 | エピセントアールエックス,インコーポレイテッド | 免疫調節融合タンパク質 |
WO2021147886A1 (zh) * | 2020-01-21 | 2021-07-29 | 张晋宇 | 一种药物组合物及其用途 |
CN113480662B (zh) * | 2021-06-29 | 2022-07-22 | 北京双因生物科技有限公司 | 包含cd40抗体和il-15的融合蛋白及其制备方法和用途 |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
US5262522A (en) | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
WO1996011213A1 (en) | 1994-10-07 | 1996-04-18 | Amgen Boulder Inc. | Dimeric il-4 inhibitors |
AUPN477695A0 (en) | 1995-08-14 | 1995-09-07 | Commonwealth Scientific And Industrial Research Organisation | Gene therapy |
GB9626029D0 (en) | 1996-12-14 | 1997-01-29 | Univ Leeds | EVH-1 vectors |
US5998598A (en) | 1997-03-10 | 1999-12-07 | The United States Of America, As Represented By The Department Of Health And Human Services | Immunoadhesins and methods of production and use thereof |
EP0975771B1 (en) | 1997-04-18 | 2007-07-11 | Biogen Idec MA Inc. | Type ii tgf-beta receptor/immunoglobulin constant region fusion proteins |
CA2330939A1 (en) | 1998-06-16 | 1999-12-23 | Biogen, Inc. | Variant type ii tgf-beta receptor fusion proteins and methods |
US6472179B2 (en) | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
US7083950B2 (en) | 1998-09-25 | 2006-08-01 | Regeneron Pharmaceuticals, Inc. | High affinity fusion proteins and therapeutic and diagnostic methods for use |
JP4944324B2 (ja) | 1999-07-13 | 2012-05-30 | ボルダー バイオテクノロジー, インコーポレイテッド | 免疫グロブリン融合タンパク質 |
AU778611B2 (en) | 1999-08-09 | 2004-12-16 | Merck Patent Gmbh | Multiple cytokine-antibody complexes |
US7638604B2 (en) | 2001-02-23 | 2009-12-29 | Genetics Institute, Llc | Monoclonal antibodies against interleukin-22 |
US20030125251A1 (en) | 2001-06-21 | 2003-07-03 | Wakefield Lalage M. | Transforming growth factor beta (TGF-beta) antagonist selectively neutralizes "pathological" TGF-beta |
US7820793B2 (en) * | 2002-02-08 | 2010-10-26 | University Of Medicine And Dentistry Of New Jersey | IFN-λ polypeptides and compositions |
WO2005028517A2 (en) | 2003-05-09 | 2005-03-31 | The General Hospital Corporation | SOLUBLE TGF-β TYPE III RECEPTOR FUSION PROTEINS |
JP4635255B2 (ja) | 2003-09-02 | 2011-02-23 | 独立行政法人産業技術総合研究所 | 抗体医薬 |
WO2006084327A1 (en) * | 2005-02-09 | 2006-08-17 | Apollo Life Sciences Limited | A molecule and chimeric molecules thereof |
WO2006084337A1 (en) * | 2005-02-14 | 2006-08-17 | Apollo Life Sciences Limited | A molecule and chimeric molecules thereof |
CN101146825A (zh) * | 2005-02-14 | 2008-03-19 | 阿波罗生命科学有限公司 | 分子及其嵌合分子 |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
US20090175819A1 (en) * | 2005-11-15 | 2009-07-09 | Apollo Life Sciences Limited | Molecule and chimeric molecules thereof |
JP5577243B2 (ja) | 2007-05-30 | 2014-08-20 | ポステク アカデミー−インダストリー ファウンデイション | 免疫グロブリン融合タンパク質 |
JP2010529859A (ja) | 2007-06-15 | 2010-09-02 | ジェンザイム、コーポレーション | TGF−βII型受容体の2つのTGF−β結合ドメインを含有する融合タンパク質 |
WO2010031168A1 (en) | 2008-09-17 | 2010-03-25 | National Research Council Of Canada | HETERO-MULTIVALENT BINDING AGENTS FOR MEMBERS OF THE TGFβ SUPERFAMILY |
US8420784B2 (en) * | 2008-05-27 | 2013-04-16 | Kyowa Hakko Kirin Co., Ltd. | Interleukin 10 receptor, (IL-10R) antibodies |
WO2010003118A1 (en) | 2008-07-02 | 2010-01-07 | Trubion Pharmaceuticals, Inc. | Tgf-b antagonist multi-target binding proteins |
ES2750305T3 (es) | 2009-03-02 | 2020-03-25 | Univ California | Mutantes de E1A y E1B de adenovirus selectivos de tumor |
EP2542590B2 (en) | 2010-03-05 | 2020-04-01 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
CN104334573A (zh) | 2012-04-30 | 2015-02-04 | 比奥孔有限公司 | 靶向/免疫调节性融合蛋白及其制造方法 |
NZ711445A (en) | 2013-03-12 | 2018-06-29 | Biocon Ltd | Fusion immunomodulatory proteins and methods for making same |
WO2015027082A1 (en) | 2013-08-22 | 2015-02-26 | Acceleron Pharma, Inc. | Tgf-beta receptor type ii variants and uses thereof |
CA2931309C (en) | 2013-11-21 | 2022-06-21 | The Brigham And Women's Hospital, Inc. | Compositions and methods for treating pulmonary hypertension |
JP6731346B2 (ja) | 2014-02-10 | 2020-07-29 | メルク パテント ゲーエムベーハー | 標的TGFβ阻害 |
AU2015364396B2 (en) | 2014-12-19 | 2018-08-09 | Alkermes, Inc. | Single chain Fc fusion proteins |
PT3288965T (pt) * | 2015-04-29 | 2019-10-15 | Mediolanum Farm S P A | Um recetor de interleucina-10 quimérico solúvel e sua utilização terapêutica |
EP3344660A4 (en) | 2015-08-31 | 2019-07-03 | National Research Council of Canada | TGF-BETA-RECEPTOR-EKTODOMÄNENFUSIONSMOLEKÜLE AND USES THEREOF |
JP7421338B2 (ja) | 2016-09-27 | 2024-01-24 | エピセントアールエックス,インコーポレイテッド | 免疫調節融合タンパク質 |
US10232053B2 (en) * | 2016-12-30 | 2019-03-19 | Trieza Therapeutics, Inc. | Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer |
-
2018
- 2018-09-27 JP JP2020517588A patent/JP2020536518A/ja not_active Withdrawn
- 2018-09-27 CA CA3077223A patent/CA3077223A1/en active Pending
- 2018-09-27 WO PCT/US2018/053197 patent/WO2019067770A1/en active Application Filing
- 2018-09-27 CN CN201880075263.5A patent/CN111511769B/zh active Active
- 2018-09-27 MX MX2020003672A patent/MX2020003672A/es unknown
- 2018-09-27 AU AU2018338612A patent/AU2018338612A1/en active Pending
- 2018-09-27 US US16/651,079 patent/US11834492B2/en active Active
- 2018-09-27 KR KR1020207011933A patent/KR20200057070A/ko not_active Application Discontinuation
- 2018-09-27 EA EA202090838A patent/EA202090838A1/ru unknown
- 2018-09-27 BR BR112020006115-8A patent/BR112020006115A2/pt unknown
- 2018-09-27 EP EP18862997.6A patent/EP3688037A4/en active Pending
- 2018-09-27 SG SG11202002826VA patent/SG11202002826VA/en unknown
-
2020
- 2020-03-26 IL IL273626A patent/IL273626A/en unknown
-
2023
- 2023-05-16 JP JP2023081001A patent/JP2023096044A/ja active Pending
- 2023-10-25 US US18/494,508 patent/US20240052016A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US11834492B2 (en) | 2023-12-05 |
AU2018338612A1 (en) | 2020-05-07 |
JP2020536518A (ja) | 2020-12-17 |
JP2023096044A (ja) | 2023-07-06 |
MX2020003672A (es) | 2020-08-03 |
CN111511769A (zh) | 2020-08-07 |
KR20200057070A (ko) | 2020-05-25 |
US20240052016A1 (en) | 2024-02-15 |
BR112020006115A2 (pt) | 2020-11-17 |
IL273626A (en) | 2020-05-31 |
EA202090838A1 (ru) | 2020-08-28 |
US20200223901A1 (en) | 2020-07-16 |
CA3077223A1 (en) | 2019-04-04 |
WO2019067770A1 (en) | 2019-04-04 |
EP3688037A1 (en) | 2020-08-05 |
CN111511769B (zh) | 2024-05-24 |
EP3688037A4 (en) | 2021-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL265657A (en) | Immunomodulatory fusion proteins | |
HK1246317A1 (zh) | 免疫調節融合蛋白及其用途 | |
HK1244019A1 (zh) | 融合蛋白 | |
GB201509413D0 (en) | Fusion protein | |
LT3180363T (lt) | Sirp-alfa imunoglobulino sulieti baltymai | |
HK1232136A1 (zh) | 融合蛋白 | |
GB201504691D0 (en) | Fusion protein | |
ZA202003845B (en) | Fusion proteins | |
GB201608197D0 (en) | Novel proteins | |
SG11202101904UA (en) | Spd-1 variant - fc fusion proteins | |
IL273626A (en) | Immunomodulatory fusion proteins | |
HK1257937A1 (zh) | 融合蛋白 | |
ZA202102533B (en) | Fusion protein | |
GB2558968B (en) | G Proteins | |
GB201602850D0 (en) | Fusion proteins | |
EP3649159C0 (en) | FUSION PROTEIN | |
GB201712792D0 (en) | Fusion protein | |
EP3647426A4 (en) | FUSION PROTEIN | |
HK1251456A1 (zh) | 免疫球蛋白融合蛋白及其用途 | |
GB201617799D0 (en) | Fusion polypeptide | |
GB201503789D0 (en) | Fusion polypeptide |